Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...

US stocks were largely lower on Wednesday as investors digested a hotter-than-expected January inflation reading. The Dow ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

As President Trump threatens a wider trade war on EU and other allies, an obscure global tax battle could be one retaliatory ...

Kraft Heinz (KHC) forecast annual profit below estimates on Wednesday, as the packaged food maker contends with sluggish ...

Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (" Hyperscale Data ” or the " Company ”), today announced that it has successfully paid 32 consecutive monthly cash dividends ...